Encephalitis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The encephalitis treatment market size is projected to be USD 11.10 billion in 2025, USD 11.82 billion in 2026, and reach USD 16.21 billion by 2031, growing at a CAGR of 6.52% from 2026 to 2031. This report is segmented by Disease Type (Primary [Viral Encephalitis and More], Secondary), Treatment Type (Antivirals, Steroids, Antibiotics, and More), Dosage Form (Injection, Tablets and Capsules, Others), Patient Age (Adult, Pediatric, Neonatal), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, and More). Forecasts are in Value (USD).

Global Encephalitis Treatment Market Trends and Insights

Rising Viral and Vector-Borne Encephalitis Burden

Herpes simplex virus remained the most frequent sporadic cause of infectious encephalitis in temperate countries, with annual incidence reported between 1.4 and 13.8 cases per 100,000 people. Japanese encephalitis causes an estimated 100,000 clinical cases globally each year and leads to approximately 25,000 deaths. These disease volumes support continuing use of antivirals, supportive medicines, and hospital-based care across the encephalitis treatment market. The burden is uneven because diagnostic access remains limited in many high-incidence settings. A 2025 analysis reported that fewer than 30% of facilities in Sub-Saharan Africa were equipped for routine HSV testing, while more than 70% of South Asian facilities lacked autoantibody panels or HSV PCR capacity. Delayed confirmation can result in longer empiric regimens, which increases the treatment period but does not resolve the underlying access gap.

Earlier Diagnosis Through Multiplex Molecular Testing and Metagenomic Sequencing

Multiplex PCR panels, including BioFire FilmArray and QIAstat-Dx ME, can detect up to 14 pathogens from one cerebrospinal fluid sample. These systems can reduce pathogen identification from days to hours and support more targeted antiviral selection. A seven-year clinical evaluation found that metagenomic next-generation sequencing identified pathogens in cases where multiplex PCR did not, with higher yield when samples were tested within 7 days of collection. Better detection can move untreated or incorrectly managed patients into appropriate drug pathways within the encephalitis treatment market. Once a panel identifies a pathogen, prescribers may be less likely to move quickly to broad immunoglobulin treatment. A multicenter evaluation reported 100% concordance for bacterial and yeast pathogens between QIAstat-Dx ME and reference methods, supporting adoption across European hospital networks.

Diagnostic Delay From Overlapping Neuroinfectious and Psychiatric Presentations

Autoimmune encephalitis can begin with behavioral or psychiatric symptoms, which can delay a neurological evaluation. A 2024 clinical update identified misdiagnosis of antibody-negative cases as a continuing problem and noted that diagnostic criteria are not applied consistently. A 2025 analysis associated delayed HSV detection beyond 6 hours from symptom onset with 30% higher mortality in low- and middle-income countries. Late presentation can limit payer and hospital willingness to authorize premium immunotherapy for severely ill patients. This reduces the share of clinical cases that become commercially accessible treatment episodes in the encephalitis treatment market. The same analysis reported that encephalitis admissions in low- and middle-income countries fell by 40% during COVID-19 because resources were diverted.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Autoimmune Encephalitis Recognition and Immunotherapy Use
• Growth of Critical-Care and Specialist Neurology Capacity
• High Cost of Intensive Care, Immunoglobulin, and Rehabilitation

Segment Analysis

Primary encephalitis held 56.31% of the encephalitis treatment market share in 2025. Its position reflects the treatment burden from well-characterized pathogens, particularly herpes simplex virus and Japanese encephalitis virus. Established protocols for these conditions provide consistent prescribing patterns. Bacterial, fungal, and parasitic forms represent a smaller share of cases. These forms can nevertheless require longer and more complex regimens, which sustains treatment value per patient. The disease category also remains closely tied to hospital diagnosis and timely initiation of therapy. This keeps acute antiviral treatment central to the encephalitis treatment market.

Secondary encephalitis is forecast to grow at a 7.88% CAGR through 2031. The category includes postinfectious, autoimmune, and systemic disease-related forms of encephalitis. A 2025 study of pediatric autoimmune encephalitis reported a 90.2% favorable outcome rate for dexamethasone combined with IVIG and reported near-zero severe adverse events. This evidence supports clinician confidence in escalating immunotherapy when appropriate. NMDAR, LGI1, and CASPR2 antibody-associated disease is receiving substantial pharmaceutical attention because of recurrence risk and targeted second-line biologics. Encephalitis related to systemic disease, including sepsis, organ failure, and metabolic disturbance, remains less clearly defined from a commercial perspective. Its treatment demand may rise as systemic disease becomes more prevalent among older populations. The shift toward secondary forms adds a longer follow-up component to the encephalitis treatment market.

Antiviral agents held 35.24% of the encephalitis treatment market share in 2025. Intravenous acyclovir remains central to viral encephalitis care and has supported high treatment volumes after patent expiry. Generic access has made the product class widely used in hospital care. A 2025 pharmacokinetic modeling study indicated that a standard acyclovir dose of 10 mg/kg intravenously 3 times daily may be inadequate for HSV and VZV encephalitis. The analysis considered 15 to 20 mg/kg every 6 hours as alternative regimens. If clinical protocols adopt optimized dosing, drug use per treatment episode could increase. Antiviral supply reliability remains important because treatment is generally initiated in the acute phase.

Immunoglobulin therapy is projected to expand at an 8.22% CAGR through 2031, making it the fastest-growing treatment type. Greater recognition of autoimmune encephalitis and evidence for IVIG in NMDAR and LGI1 disease support this progression. Steroid injections and antibiotics continue to serve infectious cases, while steroids also form part of autoimmune treatment combinations. The 2025 DexEnceph Phase 3 study found that adjunct dexamethasone did not improve verbal memory at 26 weeks in HSV encephalitis. The finding may limit steroid escalation in viral cases without changing the broader role of steroids in autoimmune protocols. FDA labeling requirements for immunoglobulin products and EMA pharmacovigilance obligations remain important because plasma-product shortages affect supply planning. These factors favor companies able to manage regulatory compliance and dependable distribution across the encephalitis treatment market.

Complete Report Scope:

• By Disease Type
  • Primary Encephalitis
    • Viral Encephalitis
    • Bacterial Encephalitis
    • Fungal Encephalitis
    • Parasitic Encephalitis
  • Secondary Encephalitis
    • Post-Infectious Encephalitis
    • Autoimmune Encephalitis
    • Encephalitis Due to Systemic Disease
• By Treatment Type
  • Antiviral Agents
    • Acyclovir
    • Ganciclovir
    • Foscarnet
    • Valacyclovir
    • Famciclovir
  • Steroid Injections
  • Antibiotics
  • Immunoglobulin Therapy
  • Other Treatment Types
• By Dosage Form
  • Injection
  • Tablets and Capsules
  • Other Dosage Forms
• By Patient Age Group
  • Adult
  • Pediatric
  • Neonatal
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of the encephalitis treatment market share in 2025. High diagnostic rates, multiplex PCR adoption, critical-care capacity, and established immunoglobulin reimbursement support the region’s position. The United States remains the largest national market in the region. The FDA continued to report active shortages for multiple immunoglobulin products in January 2026, indicating ongoing clinical reliance and supply pressure. Canada has a national immunoglobulin shortage management plan with phased alerts for hospital and regional procurement. Mexico has lower specialist neurology access outside major urban centers. This limits its treatment reach relative to the United States and Canada.

Europe is a mature treatment region centered on Germany, the United Kingdom, France, Italy, and Spain. Regulatory alignment under the EMA and national immunoglobulin governance frameworks influences purchasing and access. The United Kingdom’s 2025 preferred-supplier framework required NHS trusts to move hospital IVIG patients to framework products by September 2025. West Nile virus transmission risk has expanded into parts of southern and central Europe. Long-term warming has expanded ecologically suitable territory for the virus and increased the population at risk relative to a no-warming counterfactual. Germany and the Netherlands now face transmission risk in populations that were previously nonendemic. This extends the geographic setting for arboviral encephalitis treatment.

Asia-Pacific is forecast to grow at a 7.25% CAGR through 2031, the fastest regional rate in the encephalitis treatment market. South Asia has the highest age-standardized incidence rates, including up to 143.7 cases per 100,000 people in India. Japanese encephalitis remains endemic from India to Japan, and government immunization programs seek to address coverage gaps. Tamil Nadu expanded Japanese encephalitis vaccination to 5 additional districts in 2025 after rising cases were linked with under-vaccinated rural areas. China benefits from domestic generic manufacturing and a hospital-based delivery system. Japan and South Korea have higher specialty-drug revenue because of universal health coverage and intensive diagnosis. Indonesia, Vietnam, and Thailand remain less penetrated relative to disease burden, while the GCC has stronger access than much of Sub-Saharan Africa. Brazil is South America’s largest treatment market, with Argentina a secondary contributor as private hospital networks expand.

List of Companies Covered in this Report:

• Abbott Laboratories
• Aurobindo Pharma
• Basilea Pharmaceutica Ltd.
• Bayer
• Bharat Biotech International Limited
• Eli Lilly and Company
• Roche
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Johnson & Johnson
• Melinta Therapeutics, LLC
• Merck
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Valneva

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support